Is ALIM a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

362 people get ALIM articles and Market Currents by email alert.

Get email alerts on ALIM »

HEADLINES:

Ophthalmology Innovators: Will InSite Follow Recent Successes?
Charles Russo • Thu, May 16
Alimera Sciences And Trius Therapeutics: 2 Big Biotechs For 2013
Bob's Stocks • Mon, May 13 • 1 Comment
Alimera Sciences Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Alimera Sciences Reports First Quarter 2013 Financial Results

PR Newswire (May 9, 2013)
Alimera Sciences Secures $20 Million Debt Facility

PR Newswire (May 8, 2013)
Alimera Sciences Announces First Patient Treated With Commercially Available ILUVIEN®

PR Newswire (May 7, 2013)
Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results

PR Newswire (May 3, 2013)
Alimera Sciences Announces New PDUFA Date For ILUVIEN®

PR Newswire (May 1, 2013)
Alimera Sciences Announces ILUVIEN® Now Available In U.K.

PR Newswire (Apr 29, 2013)
For Iluvien, The FDA Isn't The Issue; European Sales Are
Andreas Spiro • Wed, Apr 24 • 2 Comments
Is The Third Time The Charm For ILUVIEN?
David Sobek • Thu, Apr 4 • 1 Comment
Alimera Sciences Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 21
Alimera Sciences Reports Fourth Quarter 2012 Financial Results

PR Newswire (Mar 21, 2013)
Alimera Sciences: About To Cash In?
Matt Kootnikoff • Tue, Mar 19 • 10 Comments
Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results

PR Newswire (Mar 11, 2013)
Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference

PR Newswire (Feb 20, 2013)
Alimera Sciences: A Sleeping Giant
Matt Kootnikoff • Tue, Feb 12 • 5 Comments
Alimera Sciences' ILUVIEN® Receives Final Published Guidance From U.K.'s NICE

PR Newswire (Jan 23, 2013)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Spain For The Treatment Of Chronic Diabetic Macular Edema

PR Newswire (Jan 17, 2013)
Alimera Sciences Signs Agreement With Quintiles for European Commercial Launch of ILUVIEN®

PR Newswire (Dec 4, 2012)

To learn more about Seeking Alpha Pro, click here.

For Iluvien, The FDA Isn't The Issue; European Sales Are
Andreas Spiro • Wed, Apr 24 • 2 Comments
Alimera Sciences: About To Cash In?
Matt Kootnikoff • Tue, Mar 19 • 10 Comments
Alimera Sciences: A Sleeping Giant
Matt Kootnikoff • Tue, Feb 12 • 5 Comments
Risky Alimera May Be Another Keryx Heading For Collapse
James Stocklasar Thomas Jr. • Wed, Apr 4, 2012 • 2 Comments
Alimera Sciences: An Upcoming Catalyst Should Make For A Nice Stock Gain
Scott Matusow • Mon, Mar 26, 2012 • 11 Comments
Alimera Clears Some of the Muddle on Eye Implant Data but Nervousness Still Warranted
EP Vantage • Sun, Feb 6, 2011
Alimera's Eye Drug Still Facing Hurdles in U.S. and U.K.
Zacks Investment Research • Tue, Dec 28, 2010 • 1 Comment
Biotech IPO: Alimera Sciences
SA Editor Abbi Adest • Wed, Apr 21, 2010

Ophthalmology Innovators: Will InSite Follow Recent Successes?
Charles Russo • Thu, May 16
Alimera Sciences And Trius Therapeutics: 2 Big Biotechs For 2013
Bob's Stocks • Mon, May 13 • 1 Comment
Is The Third Time The Charm For ILUVIEN?
David Sobek • Thu, Apr 4 • 1 Comment
Biotechnology In 2012: The Best Performing Industry
Ryan's View • Tue, Dec 4, 2012
10 Healthcare Stocks With Scheduled July Catalysts
Spencer Knight • Mon, Jul 2, 2012 • 24 Comments
Bio Pharma Momentum Movers For Today: Will Arena's Weight Loss Drug Lorcaserin Be Approved?
Scott Matusow • Wed, Jun 27, 2012 • 52 Comments
4 Stocks In The Biotech Doghouse
James Stocklasar Thomas Jr. • Wed, May 30, 2012 • 13 Comments
Bonus Round: 9 Stocks Follow-Up
James Stocklasar Thomas Jr. • Mon, Apr 23, 2012 • 17 Comments
Psivida: Small-Cap Ophthalmology-Based BioTech Positioned For Long-Term Growth
Scott Matusow • Wed, Apr 18, 2012 • 6 Comments
Which Q1 Biotech Movers Can Build Off Momentum?
Brian Nichols • Thu, Apr 12, 2012 • 3 Comments
Psivida Licensee Set For European Launch By Year's End
Len Zehr • Wed, Apr 11, 2012 • 1 Comment
Tuesday's Bio-Pharma Watch List
Scott Matusow • Tue, Mar 27, 2012 • 11 Comments
The 50 Best Performing US Stocks In 2012
Bespoke Investment Group • Mon, Mar 26, 2012 • 4 Comments
Small Cap Biotech Stocks Trading Higher
A John Hodge • Mon, Mar 19, 2012 • 8 Comments
Rising Consumer Confidence Boosts Markets
Midnight Trader • Tue, Feb 28, 2012 • 2 Comments
Biotech Class Of 2010: IPOs Revisited
Steven Breazzano • Wed, Jan 4, 2012 • 3 Comments
Noteworthy Insider Buys And Sells Across Multiple Sectors Last Week
GuruFundPicks • Sun, Nov 20, 2011 • 7 Comments
Alimera, pSivida Strike Out On Eye Implant Drug
EP Vantage • Tue, Nov 15, 2011 • 2 Comments
6 Biotech Stocks Analysts Expect To Double In 2012
Rougemont • Wed, Nov 2, 2011
5 Pharma Companies With November Catalysts
Spencer Knight • Tue, Nov 1, 2011 • 2 Comments

Alimera Sciences Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Alimera Sciences Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 21
Alimera Sciences Management Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 7, 2012
Alimera Sciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Sat, Aug 11, 2012

Alimera Sciences Reports First Quarter 2013 Financial Results

PR Newswire (May 9, 2013)
Alimera Sciences Secures $20 Million Debt Facility

PR Newswire (May 8, 2013)
Alimera Sciences Announces First Patient Treated With Commercially Available ILUVIEN®

PR Newswire (May 7, 2013)
Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results

PR Newswire (May 3, 2013)
Alimera Sciences Announces New PDUFA Date For ILUVIEN®

PR Newswire (May 1, 2013)
Alimera Sciences Announces ILUVIEN® Now Available In U.K.

PR Newswire (Apr 29, 2013)
Alimera Sciences Reports Fourth Quarter 2012 Financial Results

PR Newswire (Mar 21, 2013)
Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results

PR Newswire (Mar 11, 2013)
Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference

PR Newswire (Feb 20, 2013)
Alimera Sciences' ILUVIEN® Receives Final Published Guidance From U.K.'s NICE

PR Newswire (Jan 23, 2013)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Spain For The Treatment Of Chronic Diabetic Macular Edema

PR Newswire (Jan 17, 2013)
Alimera Sciences Signs Agreement With Quintiles for European Commercial Launch of ILUVIEN®

PR Newswire (Dec 4, 2012)
Alimera Sciences To Present At Oppenheimer 23rd Annual Healthcare Conference

PR Newswire (Dec 3, 2012)
Alimera Sciences' ILUVIEN® Receives Final Draft Guidance From U.K.'s NICE

PR Newswire (Nov 29, 2012)
Alimera Sciences Names European Management Team

PR Newswire (Nov 14, 2012)
Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference

PR Newswire (Nov 8, 2012)
Alimera Sciences Reports Third Quarter 2012 Financial Results

PR Newswire (Nov 7, 2012)
Alimera Sciences To Release Third Quarter Fiscal Year 2012 Financial Results

PR Newswire (Oct 22, 2012)
Alimera Sciences Closes $40 Million Financing

PR Newswire (Oct 2, 2012)
U.K.'s National Institute for Health and Clinical Evidence Accepts Alimera Sciences' ILUVIEN® Subgroup Data for Review

PR Newswire (Sep 5, 2012)

ALIM vs. ETF Alternatives

Company Description

Currently, there's no company description for ALIM.

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United States

johnjail
yesterday opened a little position in ALIM, today +10%, good entry :)
7/19/12
Reply (1)

• !Report Abuse
View all 1 replies
johnjail: psivida +54%.. it has a drugs together with alim.. not so good that 10%... :(
7/19/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$ALIM, $ARNA, $AEZS, $ATRS, $PSDV mentioned in my new article due out pre market today.
6/27/12
Reply (10)

• !Report Abuse
View all 10 replies
onehardroll: Phemale60, it's still going down......when will we know if it's approved or not?
6/27/12
• !Report Abuse
nkimidi: Hi Scott, what is a good price to buy ATRS?
6/27/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Something might be up with $PSDV besides the relation to $ALIM, I know they are working on things, and the time is right for news
6/26/12
Reply (7)

• !Report Abuse
View all 7 replies
counsel0857: Personally I think ATRS is doing great. If I hadn't gone all-in in OMPI I would load the boat on ATRS. A "down" day like this is expected!
6/26/12
• !Report Abuse
stncws1: i will grab some ATRS when down day approached
6/26/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://stks.co/3lxm Tomorrow premarket earning $RDY, $NVDA, SOL, $RNF, URRE, CBMX, AMOT, ALIM
5/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
$PSDV making the move I anticipated, $ALIM has not so far, but believe it will, but have lowered ST target to 4.10
3/27/12
Reply (8)

• !Report Abuse
View all 8 replies
Winning Will: so after todays hard fall what do you think of ALIM for the rest of the week
3/28/12
• !Report Abuse
Scott Matusow: $CHTP was halted couple of hours ago. $ALIM i adjusted the short term pop in stock talk to 4.10 when stock was 3.80, prob stable pps now
3/28/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Looking for both $ALIM and $PSDV to make a significant move upwards today in advance of EU approval of their Implant ILUVIEN.
3/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
Give $ALIM an hour or 2, should start to move considerably higher towards 4.
3/26/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
My Next Pick; Alimera Sciences (ALIM) Video @ http://bit.ly/GS61Cd Disclosure: I hold ALIM stock
3/26/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
My next pick for next week first feature is ALIM
3/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

timtrading
$ALIM - 80% gain today http://bit.ly/zb0NqX)/
2/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

johnjail
yesterday opened a little position in ALIM, today +10%, good entry :)
7/19/12
Reply (1)

• !Report Abuse
View all 1 replies
johnjail: psivida +54%.. it has a drugs together with alim.. not so good that 10%... :(
7/19/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$ALIM, $ARNA, $AEZS, $ATRS, $PSDV mentioned in my new article due out pre market today.
6/27/12
Reply (10)

• !Report Abuse
View all 10 replies
onehardroll: Phemale60, it's still going down......when will we know if it's approved or not?
6/27/12
• !Report Abuse
nkimidi: Hi Scott, what is a good price to buy ATRS?
6/27/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Something might be up with $PSDV besides the relation to $ALIM, I know they are working on things, and the time is right for news
6/26/12
Reply (7)

• !Report Abuse
View all 7 replies
counsel0857: Personally I think ATRS is doing great. If I hadn't gone all-in in OMPI I would load the boat on ATRS. A "down" day like this is expected!
6/26/12
• !Report Abuse
stncws1: i will grab some ATRS when down day approached
6/26/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$PSDV making the move I anticipated, $ALIM has not so far, but believe it will, but have lowered ST target to 4.10
3/27/12
Reply (8)

• !Report Abuse
View all 8 replies
Winning Will: so after todays hard fall what do you think of ALIM for the rest of the week
3/28/12
• !Report Abuse
Scott Matusow: $CHTP was halted couple of hours ago. $ALIM i adjusted the short term pop in stock talk to 4.10 when stock was 3.80, prob stable pps now
3/28/12
• !Report Abuse
Add a reply...

140 characters

ALIM Alimera Sciences, Inc.

ALIM

Alimera Sciences, Inc.